{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"contributor": "", "original": "By REUTERS", "person": [], "organization": "REUTERS"}, "abstract": "United States District Court Judge Richard Seeborg denies Amgen's attempt to block sale of Novartis's recently approved biosimilar form of Neupogen, used to prevent infections in cancer patients.", "type_of_material": "News", "word_count": "258", "lead_paragraph": "Novartis&#8217;s drug, Zarxio, contains the same active ingredient as Amgen&#8217;s Neupogen, and once released would become the first biosimilar in the United States.", "pub_date": "2015-03-20T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Judge Rejects Bid by Amgen to Block Biosimilar Drug by Novartis ", "print_headline": "Business Briefing; Amgen Loses Bid to Block Biosimilar Drug by Novartis"}, "snippet": "Novartis&#8217;s drug, Zarxio, contains the same active ingredient as Amgen&#8217;s Neupogen, and once released would become the first biosimilar in the United States.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/03/20/business/judge-rejects-bid-by-amgen-to-block-biosimilar-drug-by-novartis.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Amgen Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Novartis AG", "name": "organizations"}, {"rank": "3", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}], "blog": [], "_id": "550b6aa638f0d8631c7b1173", "source": "The New York Times"}